Videos

The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.

The professor from The University of Texas MD Anderson Cancer discussed the impact that brexucabtagene autoleucel's approval has had on mantle cell lymphoma.

The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.

Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies.

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Allen Feng, PhD, chief scientific officer, HebeCell, discussed the company’s NK cell technologies.

The hematologist/oncologist discussed unmet needs and novel therapies in multiple myeloma and give practical advice for community oncologists.

The director of the Powell Gene Therapy Center at the University of Florida discussed adverse events in gene therapies.

Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, discussed the company’s pipeline and technologies.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed safety concerns with CAR T-cell therapies.

The chair of the International Collaborative Gaucher Group Registry discussed the place of gene therapies in the Gaucher treatment landscape.

The chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.

The associate professor from The University of Texas MD Anderson Cancer Center discussed eligibility for autologous stem cell transplant in patients with multiple myeloma.

Allen Feng, PhD, chief scientific officer, HebeCell, discussed advantages of induced pluripotent over hematopoietic stem cell therapies.

The director of the Powell Gene Therapy Center at the University of Florida discussed the recent meeting of the FDA Cellular, Tissue, and Gene Therapies Advisory Committee.

The chief of translational Research and immunotherapy at The Angeles Clinic and Research Institute discussed the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed key findings from the phase 2 KarMMA trial.

The chief executive and chief medical officers of Vor Biopharma discussed their focus on AML, CD33, and their lead program VOR33.

Directors from the Moran Eye Center discussed researching gene therapy approaches targeting HTRA1 in AMD.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed JQ1 and other BET inhibitors he would like to study.

The hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Experts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.

The director of the Powell Gene Therapy Center at the University of Florida discussed gene therapy programs being conducted for Pompe disease.

The associate professor from the UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center discussed the challenges faced with CAR T-cell therapy in patients with multiple myeloma.